Different cytokine profiles in cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a quantitative study of open lung biopsies

Differences in the inflammatory response and prognosis of cryptogenic fibrosing alveolitis (CFA) and that associated with systemic sclerosis (FASSc) are beginning to emerge. It is hypothesized that these differences may be reflected in a distinct pattern of T-helper (Th)-1 and Th-2-type cytokines. Open lung biopsies were obtained from clinically well-documented cases of CFA and FASSc and, as a control, compared with grossly and histologically normal parenchyma obtained from smokers whose lungs were resected for cancer (n=5 in each group). In situ hybridization (ISH) was applied to the samples using anti-sense and sense 35S-labelled riboprobes to detect messenger ribonucleic acid (mRNA) for interleukins (IL)-2, IL-4, IL-5 and interferon (IFN)-gamma. Between 52-91% of cells expressing the cytokines studied were present in the alveolar interstitium rather than in lumenal cells or the alveolar epithelial lining. The highest values for all four cytokines were present in the patients with FASSc, i.e., 22-39 ISH positive cells x mm(-2) alveolar tissue compared with 1-19 cells x mm(-2) and 4-5 cell x mm(-2) in CFA and control subjects, respectively. Whereas the proportions of the four cytokines in FASSc were similar to the control subjects, IL-4 and IL-5 predominated significantly in CFA (p<0.001). For example, the ratio of IL-5 to IFN-gamma was 22:1 in CFA, significantly higher than in the cases with FASSc (2:1) or the control subjects (4:1) (p<0.05). In conclusion, cryptogenic fibrosing alveolitis is an inflammatory condition which is characterized, like asthma, by a predominance of gene expression for T-helper-2-type regulatory cytokines, whereas cryptogenic fibrosing alveolitis associated with systemic sclerosis appears to have a distinct mixed T-helper-1/T-helper-2 functional phenotype and a greater number of cells expressing each of these pro-inflammatory cytokines.

This article has been cited by other articles:

				Q. Ye, Y. Dalavanga, N. Poulakis, S. U. Sixt, J. Guzman, and U. Costabel Decreased expression of haem oxygenase-1 by alveolar macrophages in idiopathic pulmonary fibrosis Eur. Respir. J., May 1, 2008; 31(5): 1030 - 1036. [Abstract] [Full Text] [PDF]

				T J Williams and J W Wilson Challenges in pulmonary fibrosis: 7 {middle dot} Novel therapies and lung transplantation Thorax, March 1, 2008; 63(3): 277 - 284. [Abstract] [Full Text] [PDF]

				R. M. du Bois State of the Art. Mechanisms of Scleroderma-induced Lung Disease Proceedings of the ATS, August 15, 2007; 4(5): 434 - 438. [Abstract] [Full Text] [PDF]

				Y. M. Shim, Z. Zhu, T. Zheng, C. G. Lee, R. J. Homer, B. Ma, and J. A. Elias Role of 5-Lipoxygenase in IL-13-Induced Pulmonary Inflammation and Remodeling J. Immunol., August 1, 2006; 177(3): 1918 - 1924. [Abstract] [Full Text] [PDF]

				C. G. Lee, H.-R. Kang, R. J. Homer, G. Chupp, and J. A. Elias Transgenic Modeling of Transforming Growth Factor-{beta}1: Role of Apoptosis in Fibrosis and Alveolar Remodeling. Proceedings of the ATS, July 1, 2006; 3(5): 418 - 423. [Abstract] [Full Text] [PDF]

				P. Pignatti, G. Brunetti, D. Moretto, M.-R. Yacoub, M. Fiori, B. Balbi, A. Balestrino, G. Cervio, S. Nava, and G. Moscato Role of the Chemokine Receptors CXCR3 and CCR4 in Human Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., February 1, 2006; 173(3): 310 - 317. [Abstract] [Full Text] [PDF]

				J. L. Chunn, J. G. Molina, T. Mi, Y. Xia, R. E. Kellems, and M. R. Blackburn Adenosine-Dependent Pulmonary Fibrosis in Adenosine Deaminase-Deficient Mice J. Immunol., August 1, 2005; 175(3): 1937 - 1946. [Abstract] [Full Text] [PDF]

				C. G. Lee, S. J. Cho, M. J. Kang, S. P. Chapoval, P. J. Lee, P. W. Noble, T. Yehualaeshet, B. Lu, R. A. Flavell, J. Milbrandt, et al. Early Growth Response Gene 1-mediated Apoptosis Is Essential for Transforming Growth Factor {beta}1-induced Pulmonary Fibrosis J. Exp. Med., August 2, 2004; 200(3): 377 - 389. [Abstract] [Full Text] [PDF]

				N. Khalil and R. O'Connor Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment Can. Med. Assoc. J., July 20, 2004; 171(2): 153 - 160. [Abstract] [Full Text] [PDF]

				R. F. Hamilton Jr., E. Parsley, and A. Holian Alveolar macrophages from systemic sclerosis patients: evidence for IL-4-mediated phenotype changes Am J Physiol Lung Cell Mol Physiol, June 1, 2004; 286(6): L1202 - L1209. [Abstract] [Full Text] [PDF]

				C Jakubzick, E S Choi, S L Kunkel, H Evanoff, F J Martinez, R K Puri, K R Flaherty, G B Toews, T V Colby, E A Kazerooni, et al. Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia J. Clin. Pathol., May 1, 2004; 57(5): 477 - 486. [Abstract] [Full Text] [PDF]

				U. Costabel Idiopathic pulmonary fibrosis: a treatable disease? Eur. Respir. J., December 1, 2003; 22(6): 872 - 873. [Full Text] [PDF]

				M. W. Wynes and D. W. H. Riches Induction of Macrophage Insulin-Like Growth Factor-I Expression by the Th2 Cytokines IL-4 and IL-13 J. Immunol., October 1, 2003; 171(7): 3550 - 3559. [Abstract] [Full Text] [PDF]

				N. G. Sandler, M. M. Mentink-Kane, A. W. Cheever, and T. A. Wynn Global Gene Expression Profiles During Acute Pathogen-Induced Pulmonary Inflammation Reveal Divergent Roles for Th1 and Th2 Responses in Tissue Repair J. Immunol., October 1, 2003; 171(7): 3655 - 3667. [Abstract] [Full Text] [PDF]

				K. R. Flaherty, T. V. Colby, W. D. Travis, G. B. Toews, J. Mumford, S. Murray, V. J. Thannickal, E. A. Kazerooni, B. H. Gross, J. P. Lynch III, et al. Fibroblastic Foci in Usual Interstitial Pneumonia: Idiopathic versus Collagen Vascular Disease Am. J. Respir. Crit. Care Med., May 15, 2003; 167(10): 1410 - 1415. [Abstract] [Full Text] [PDF]

				M. G. Chiaramonte, M. Mentink-Kane, B. A. Jacobson, A. W. Cheever, M. J. Whitters, M. E.P. Goad, A. Wong, M. Collins, D. D. Donaldson, M. J. Grusby, et al. Regulation and Function of the Interleukin 13 Receptor {alpha} 2 During a T Helper Cell Type 2-dominant Immune Response J. Exp. Med., March 17, 2003; 197(6): 687 - 701. [Abstract] [Full Text] [PDF]

				J. ZHU, S. MAJUMDAR, Y. QIU, T. ANSARI, A. OLIVA, J. C. KIPS, R. A. PAUWELS, V. DE ROSE, and P. K. JEFFERY Interleukin-4 and Interleukin-5 Gene Expression and Inflammation in the Mucus-secreting Glands and Subepithelial Tissue of Smokers with Chronic Bronchitis . Lack of Relationship with CD8+ Cells Am. J. Respir. Crit. Care Med., December 15, 2001; 164(12): 2220 - 2228. [Abstract] [Full Text] [PDF]

				C. G. Lee, R. J. Homer, Z. Zhu, S. Lanone, X. Wang, V. Koteliansky, J. M. Shipley, P. Gotwals, P. Noble, Q. Chen, et al. Interleukin-13 Induces Tissue Fibrosis by Selectively Stimulating and Activating Transforming Growth Factor {beta}1 J. Exp. Med., September 17, 2001; 194(6): 809 - 822. [Abstract] [Full Text] [PDF]

				G. W. Hoyle and A. R. Brody IL-9 and Lung Fibrosis . A Th2 Good Guy? Am. J. Respir. Cell Mol. Biol., April 1, 2001; 24(4): 365 - 367. [Full Text]

				M. Arras, F. Huaux, A. Vink, M. Delos, J.-P. Coutelier, M.-C. Many, V. Barbarin, J.-C. Renauld, and D. Lison Interleukin-9 Reduces Lung Fibrosis and Type 2 Immune Polarization Induced by Silica Particles in a Murine Model Am. J. Respir. Cell Mol. Biol., April 1, 2001; 24(4): 368 - 375. [Abstract] [Full Text]

				Z. Wang, T. Zheng, Z. Zhu, R. J. Homer, R. J. Riese, H. A. Chapman Jr., S. D. Shapiro, and J. A. Elias Interferon {gamma} Induction of Pulmonary Emphysema in the Adult Murine Lung J. Exp. Med., December 4, 2000; 192(11): 1587 - 1600. [Abstract] [Full Text] [PDF]

				R.M. du Bois Interferon Gamma-1b for the Treatment of Idiopathic Pulmonary Fibrosis N. Engl. J. Med., October 21, 1999; 341(17): 1302 - 1304. [Full Text]